Geopolitical shocks can rattle markets quickly, but they also spotlight companies whose dividends and balance sheets may help steady a portfolio. With U.S. strikes on Iran, rising oil prices, and higher volatility, investors are again testing which stocks can handle sharper swings without abandoning income. This article looks at three high quality dividend stocks from our screener that appear closely exposed to the latest headlines. Each stock has large cap scale, a record of paying dividends, and relatively solid financial profiles. This may give you a clearer starting point for deciding whether to lean in, or stay cautious, around this news driven setup.

Bristol-Myers Squibb (BMY)

Overview: Bristol-Myers Squibb is a global biopharmaceutical company that develops, manufactures, and sells prescription medicines across cancer, blood disorders, immune diseases, cardiovascular conditions, and neuroscience, including well known therapies such as Opdivo, Eliquis, Revlimid, and Camzyos.

Operations: Bristol-Myers Squibb generates all of its US$48.5b in revenue from pharmaceuticals, with around US$33.2b from the United States, US$14.2b from international markets, and the remainder unallocated.

Market Cap: US$118.4b

For income focused investors watching the latest headlines, Bristol-Myers Squibb stands out as a large cap pharmaceutical stock combining a 4.38% dividend yield, improved net margins at 15%, and a wide portfolio of late stage oncology and cardiovascular drugs that may help offset future patent expiries. Recent EU and US approvals for therapies like Opdivo and Sotyktu, plus regulatory momentum around Camzyos and new cell therapy data, indicate how the pipeline is being advanced even as older blockbusters face pressure and drug pricing reforms add uncertainty. High debt and forecasts for declining revenue and earnings over the next few years mean this is not a set and forget income play, but rather a complex risk reward story that defensive dividend investors may want to understand in detail.

Bristol-Myers Squibb’s 4.38% yield and 15% net margin hint at a story investors may be only half seeing; the real question is how the pipeline and balance sheet fit together in the Bristol-Myers Squibb financial health report

National Fuel Gas (NFG)

Overview: National Fuel Gas is a diversified U.S. energy company that produces natural gas, transports and stores it through interstate pipelines, and sells it directly to households and businesses through its regulated utility operations in New York and Pennsylvania.

Operations: National Fuel Gas generates about US$1.3b from Integrated Upstream and Gathering, US$930.5m from its Utility segment, and US$429.8m from Pipeline and Storage, with modest corporate eliminations, all from within the United States.

Market Cap: US$7.6b

National Fuel Gas offers a mix of regulated utility cash flows, a 2.71% dividend, and vertically integrated gas operations that many investors look for when markets are on edge. The company benefits from long lived Marcellus Shale resources, efficiency moves like electric fracturing, and an Ohio utility acquisition that is expected to increase the regulated rate base and earnings stability. It is trading on a P/E below the broader U.S. market and sector averages. The trade off is meaningful leverage, exposure to long term decarbonization policy, and moderate forecast growth, which puts real focus on how resilient margins, regulation, and project execution can be over time.

Vertical integration at National Fuel Gas could be masking an underappreciated mix of stability and potential rewards, and the market may be missing what really matters in the 5 key rewards and 1 important warning sign

Hikma Pharmaceuticals (LSE:HIK)

Overview: Hikma Pharmaceuticals develops and sells generic, specialty, and branded medicines across injectables, oral, respiratory, and other dosage forms, supplying hospitals and retail markets in areas such as respiratory, oncology, and pain management across the UK, Europe, North America, the Middle East, North Africa, and beyond.

Operations: Hikma Pharmaceuticals generates most of its revenue from Injectables (US$1.4b), Hikma Rx (US$1.0b), and Branded products (US$849m), with a smaller contribution from Others (US$40m).

Market Cap: £3.5b

Hikma Pharmaceuticals is attracting attention as a defensive pharma stock that combines a 3.84% dividend yield, 12% net margins, and a broad portfolio of complex generics and injectables supported by expanding manufacturing in the US, Europe, and MENA. The stock trades on a P/E of 11.6x, below both peer and European pharma averages. At the same time, high debt, margin pressure from competition and regional mix, and FX and regulatory risks mean the story is far from straightforward, and the gap between current pricing and estimated fair value leaves a range of factors for investors to consider.

Hikma Pharmaceuticals looks like an overlooked income and complex generics story, with a 3.84% yield, 12% net margins, and a P/E of 11.6x that invites a closer look at the 3 key rewards and 2 important warning signs

The three stocks covered here are just a starting point, and the full High-Quality Dividend Stocks screener has identified 8 more large cap companies with solid balance sheets, consistent dividends, and equally compelling narratives in the High-Quality Dividend Stocks screener. Using Simply Wall St, you can quickly filter for the specific catalysts, dividend profiles, and risk factors that matter most and identify the income ideas that best fit your highest conviction plays.

Take Control of Your Investment Journey

If Bristol-Myers Squibb or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Momentum Flies

Fresh stock ideas can move from quiet to breakout quickly, and once momentum is caught, ideal entries shrink fast. Scan these under the radar lists now and get in early.

• Spot income workhorses built for staying power by reviewing a curated 9 dividend fortresses that focuses on durability as much as yield.
• Ride the infrastructure ripple effect with a focused set of 35 power grid technology and infrastructure stocks that tie into long term electrification and grid upgrade spending.
• Get ahead of the next automation wave using a hand picked pool of 30 robotics and automation stocks that sit at the heart of factories, logistics, and smart devices.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.